atyr
pharma
announces
completion
enrollment
phase
clinical
trial
patients
severe
respiratory
complications
topline
results
expected
fourth
quarter
trial
evaluating
preliminary
safety
efficacy
vs
placebo
exceeded
enrollment
san
diego
globe
newswire
atyr
pharma
nasdaq
life
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
today
announced
completed
enrollment
phase
clinical
trial
lead
therapeutic
candidate
patients
severe
respiratory
complications
study
enrolled
total
patients
hospitals
puerto
rico
exceeding
target
enrollment
patients
company
expects
report
topline
data
trial
end
year
pleased
completed
full
enrollment
study
important
step
forward
effort
aid
fight
global
pandemic
said
sanjay
shukla
president
chief
executive
officer
atyr
throughout
course
year
continued
advance
knowledge
disease
pathology
many
patients
includes
form
interstitial
pneumonia
causes
severe
respiratory
complications
lead
lung
damage
believe
leverages
newly
discovered
biological
pathways
excessive
inflammatory
responses
may
restore
immune
balance
lung
offering
potential
differentiated
approach
treat
subset
patients
severe
lung
inflammation
limited
available
treatment
options
look
forward
sharing
topline
results
study
later
phase
clinical
trial
randomized
double
blind
study
hospitalized
patients
severe
respiratory
complications
require
mechanical
ventilation
patients
enrolled
trial
randomized
single
intravenous
dose
either
mg
kg
placebo
patients
followed
days
post
treatment
trial
designed
evaluate
preliminary
safety
efficacy
compared
placebo
assessment
key
clinical
outcome
measures
atyr
developing
potential
therapeutic
patients
inflammatory
lung
diseases
fusion
protein
comprised
domain
histidyl
trna
synthetase
fused
fc
region
human
antibody
selective
modulator
downregulates
innate
adaptive
immune
response
inflammatory
disease
states
atyr
currently
enrolling
phase
trial
evaluating
patients
pulmonary
sarcoidosis
form
interstitial
lung
disease
phase
study
dose
study
designed
evaluate
safety
tolerability
steroid
sparing
effect
immunogenicity
pharmacokinetics
profile
multiple
doses
response
pandemic
atyr
conducting
phase
clinical
trial
patients
severe
respiratory
complications
phase
study
randomized
double
blind
study
designed
evaluate
safety
preliminary
efficacy
single
dose
atyr
atyr
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
atyr
research
development
efforts
concentrated
newly
discovered
area
biology
extracellular
functionality
signaling
pathways
trna
synthetases
atyr
built
global
intellectual
property
estate
directed
potential
pipeline
protein
compositions
derived
trna
synthetase
genes
extracellular
targets
atyr
primary
focus
product
candidate
binds
receptor
designed
immune
engagement
inflammatory
lung
diseases
information
please
visit
http
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
usually
identified
use
words
anticipates
believes
estimates
expects
intends
may
plans
projects
seeks
variations
words
similar
expressions
intend
statements
covered
safe
harbor
provisions
statements
making
statement
purposes
complying
safe
harbor
provisions
statements
include
statements
regarding
potential
therapeutic
benefits
applications
timelines
plans
respect
certain
development
activities
timing
data
clinical
trials
certain
development
goals
statements
also
reflect
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
us
assumptions
made
although
believe
plans
intentions
expectations
strategies
prospects
reflected
suggested
statements
reasonable
give
assurance
plans
intentions
expectations
strategies
attained
achieved
statements
based
estimates
assumptions
management
although
believe
reasonable
inherently
uncertain
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
control
including
without
limitation
uncertainty
regarding
pandemic
risks
associated
discovery
development
regulation
product
candidates
risk
partners
may
cease
delay
preclinical
clinical
development
activities
existing
future
product
candidates
variety
reasons
including
difficulties
delays
completing
clinical
trials
negative
data
preclinical
studies
clinical
trials
risk
may
able
raise
additional
funding
required
business
product
development
plans
well
risks
set
forth
recent
annual
report
form
quarterly
reports
form
sec
filings
except
required
law
assume
obligation
update
publicly
statements
whether
result
new
information
future
events
otherwise
